Previous 10 | Next 10 |
2023-12-20 08:30:00 ET Summary Point Biopharma and Lantheus Holdings released positive topline results for their radioligand therapy in patients with metastatic castration-resistant prostate cancer. The SPLASH trial met its primary endpoint, showing a progression-free survival ben...
2023-12-20 05:10:00 ET Dividend stocks can be excellent sources of recurring income for your portfolio. Stocks that increase their payouts over time can be even more valuable for long-term investors, as this income could rise in the years ahead. Three stocks that recently boosted their ...
2023-12-19 12:56:59 ET Summary Pfizer has underperformed compared to Eli Lilly in recent years, but now appears to be a more attractive investment with fewer risks. Pfizer is more diversified, while Eli Lilly is heavily dependent on a single drug, making it riskier. Pfizer is ...
2023-12-19 08:10:00 ET Summary Amgen is a biotech company with a strong track record of returning capital to shareholders and maintaining high profitability. The company has outperformed the S&P 500 and other pharmaceutical peers in terms of total returns over the past decade....
2023-12-18 23:45:02 ET Goldman Sachs analyst issues NEUTRAL recommendation for LLY on December 19, 2023 12:03AM ET. The previous analyst recommendation was Neutral. LLY was trading at $579.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2023-12-18 23:16:26 ET Summary Lantheus stock dropped 26% post-SPLASH study, highlighting risks in mCRPC drug development and its strategic alliance with POINT Biopharma. SPLASH trial met primary goals but showed underwhelming overall survival data, affecting investor confidence a...
2023-12-18 20:23:18 ET Summary Chase Coleman's Tiger Global Management 13F portfolio value increased from $11.97B to $13.56B this quarter. The largest five positions in the portfolio are Meta Platforms, Microsoft, Apollo Global, Take-Two Interactive, and Alphabet. New stakes i...
2023-12-18 12:47:56 ET More on Structure Therapeutics Structure Therapeutics: Tipping The Scales In Obesity Management Pfizer hits new 52-week low after weight loss setback Leerink sees Structure Therapeutics stock as "undervalued" Historical earnings data fo...
2023-12-18 12:22:24 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Be Cautious Of High Valuations Top overweight stocks with high free cash flow and EPS growth - MS Top stocks with earning stability and quality + overweight - MS Seeking Alpha’s Q...
2023-12-18 11:44:54 ET More on Eli Lilly Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly and Company (LLY) Presents at 6th Evercore ISI HealthCONx Conference (Transcript) Eli Lilly: Perfectly Priced Healthcare Giant ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...